Fifth PD-1, Zavicefta, Novel Psoriasis Ointment Among Latest China Approvals
Jiangsu Hengrui’s anti-PD-1 antibody is the latest to hit the immuno-oncology market in China, ensuring a fierce battle in pricing and reimbursement. Other recent new approvals include Pfizer’s antibacterial Zavicefta and a first-in-class topical treatment for psoriasis.
You may also be interested in...
2019 will be remembered as a banner year for international drug makers as many grew at phenomenal rates in China, despite expansion of the “4+7” centralized procurement scheme and steep price cuts in exchange for reimbursement. As the government continues to emphasize affordability for cancer drugs and major anti-infectives, competition is heating up quickly and immune-oncology alone has seen six PD-1s elbowing each other for market share.
Beijing-based BeiGene is set to score two big wins in a row as it pursues innovation. After securing US approval for its BTK inhibitor zanubrutinib for mantle cell lymphoma, its PD-1 inhibitor has sailed through a technical review in China.
As China embraces novel new drugs, oncology is quickly becoming the biggest opportunity for pharma to drive growth in this market. Amgen is the latest to jump on board through the purchase of a significant stake in BeiGene.